secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANI PHARMACEUTICALS INC (ANIP)
CIK:        0001023024
Form:       8-K
Filed at:   2024-05-10T23:59:59+00:00
Accession:  0001023024-24-000055
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ANI Pharmaceuticals Q1 2024: record revenue $137.4M, EPS $0.82; reiterates FY guidance
--------------------------------------------------------------------------------

- Q1 net revenue $137.4M (+28.7% YoY); GAAP diluted EPS $0.82 vs $0.06; adjusted non-GAAP EPS $1.21.
- Rare Disease segment (Cortrophin Gel) revenue $36.9M, up 126.2% YoY on higher volume.
- Generics, Established Brands and Other segment revenue $100.5M, up 11.1% YoY; launched six new generics.
- FY2024 guidance reaffirmed: revenue $520M-$542M; adjusted EBITDA $135M-$145M; adjusted EPS $4.26-$4.67.
- Ended quarter with $228.6M cash; sold Oakville facility for $14.2M, recognized $9.7M gain on CG Oncology IPO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1023024/000102302424000055/0001023024-24-000055-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1023024/000102302424000055/ani-20240510.htm
  HTML page:      https://secwatch.observer/filing/0001023024-24-000055

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer